The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study

(186)Re-1,1-hydroxyethylidene diphosphonate (etidronate) can be used for the palliative treatment of metastatic bone pain. A randomized, placebo-controlled study using (186)Re-etidronate was conducted on end-stage prostate cancer patients with metastatic bone pain. Pain relief was assessed using an...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Journal of nuclear medicine (1978) 2002-09, Vol.43 (9), p.1150
Hauptverfasser:	Han, Shiuw H, de Klerk, John M H, Tan, Suzy, van het Schip, Alfred D, Derksen, Bert H, van Dijk, Aalt, Kruitwagen, Cas L J J, Blijham, Geert H, van Rijk, Peter P, Zonnenberg, Bernard A
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Bone Neoplasms - radiotherapy Bone Neoplasms - secondary Double-Blind Method Etidronic Acid - therapeutic use Humans Male Organometallic Compounds - therapeutic use Pain Measurement Palliative Care Prostatic Neoplasms - pathology Radiopharmaceuticals - therapeutic use Rhenium - therapeutic use Tin Radioisotopes - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!